India markets close in 4 hours 3 minutes
  • BSE SENSEX

    48,058.28
    -485.78 (-1.00%)
     
  • Nifty 50

    14,371.65
    -133.15 (-0.92%)
     
  • USD/INR

    75.0980
    +0.0480 (+0.06%)
     
  • Dow

    33,730.89
    +53.62 (+0.16%)
     
  • Nasdaq

    13,857.84
    -138.26 (-0.99%)
     
  • BTC-INR

    4,754,514.00
    -64,006.50 (-1.33%)
     
  • CMC Crypto 200

    1,381.78
    +6.00 (+0.44%)
     
  • Hang Seng

    28,612.65
    -288.18 (-1.00%)
     
  • Nikkei

    29,624.09
    +3.10 (+0.01%)
     
  • EUR/INR

    89.9375
    -0.0052 (-0.01%)
     
  • GBP/INR

    103.4503
    +0.0545 (+0.05%)
     
  • AED/INR

    20.3950
    +0.0060 (+0.03%)
     
  • INR/JPY

    1.4478
    -0.0008 (-0.06%)
     
  • SGD/INR

    56.2180
    +0.0250 (+0.04%)
     

Human Microbiome Market - Global Growth, Trends, COVID-19 Impact and Forecast to 2026 - ResearchAndMarkets.com

·5-min read

The "Human Microbiome Market - Growth, Trends, COVID-19 Impact and Forecast (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.

The global human microbiome market is expected to register a CAGR of nearly 17% over the forecast period.

In recent times, the human microbiome has become an area of interest because of its association with several respiratory diseases and immunity. The gut microbiome has been known to be associated with the good immunity of a person. Researchers have reported that variation in the number of microorganisms such as actinobacteria, firmicute, and bacteroidetes leads to the development of lung, respiratory, diabetes, arthritis, gastrointestinal disorders, and other neurological disorders.

In 2020, as per the article published in Human Microbiome Journal "Lung microbiome and COVID-19: Possible link and implications", lung microbiome can have a profound impact on the severity of the disease and susceptibility to SARS-CoV-2 infection. Also, the study suggested that the lung microbiome plays a crucial role in the generation of immune responses against viral attack, and the microbiome may affect the outcome of COVID-19. Thus, increasing research studies in the arena of the microbiome are the key drivers affirming the growth of this market.

The other key factors propelling the growth of this market are increasing burden of lifestyle-related diseases and growing geriatric population. Lowering the level of microbiota will leads to the growth of fatal infectious diseases and organisms, such as ulcerative colitis. C and Clostridium difficile (C. difficile). Antimicrobial Resistance (AMR) in the peple who are taking anitiobiotcs for prolonged period is also helping the market to grow.

For instance, as per the data published by Centers for Disease Control and Prevention, in the United States, around 2.8 million antibiotic-resistant infections occur each year. Also, 223,900 cases of Clostridioides difficile occurred in 2017 and around 12,800 people died. As a result of increasing cases, the market is expected to increase in the upcoming years.

Increasing funding initiatives and government programs to support this research are high impact rendering drivers anticipated to foster market growth. In 2019, the "Million Microbiome of Humans Project" (MMHP) was launched at the 14th International Conference on Genomics (ICG-14) in China. Thus, such government initiatives pertaining to high market growth.

However, lack of comprehensive research and stringent government regulations is likely to limit the market growth over forecast period.

Key Market Trends

Therapeutic Applications is Expected to Hold the Highest Share over the Forecast Period

Microbiome therapeutics has found a broad range of applications in the arena of Covid- 19, Inflammatory Bowel Disease (IBD), C. difficile infections, Crohn's disease, and diabetes. Rising research activities undertaken by research institutes for finding more therapeutic applications of the human microbiome are expected to accentuate growth.

For instance, in 2020, the University of Zurich is also investigating the microbiota in COVID-19 patients for future preventive and therapeutic approaches (MICRO-COV). Positive results from these research studies will open up the growth avenues to the segment studied.

Furthermore, the rising efforts of pharmaceutical companies for the development of novel drugs is also a high impact rendering factor for growth. According to a report by Seventure Partners, a French VC investor, in 2018 alone, over 2400 clinical trials were registered as the testing therapies on microbiome science.

Competitive Landscape

The human microbiome market is less competitive and there are several players that are coming up with new products. Companies, like Yakult, DuPont, Series Therapeutics, Second Genome, and Synthetic Biologics, hold substantial shares in the market. Key players are focusing on enhancing the therapeutics pipeline through the development of efficient and safe drugs.

Key Topics Covered:

1 INTRODUCTION

1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Increasing Incidence of Lifestyle-related Diseases

4.2.2 Growing Geriatric Population

4.3 Market Restraints

4.3.1 Lack of Comprehensive Research

4.3.2 Stringent Government Regulations

4.4 Porter's Five Forces Analysis

5 MARKET SEGMENTATION

5.1 By Application

5.1.1 Therapeutics

5.1.2 Diagnostics

5.2 By Disease

5.2.1 Obesity

5.2.2 Diabetes

5.2.3 Autoimmune Disorder

5.2.4 Cancer

5.2.5 Gastrointestinal Disorders

5.2.6 Central Nervous System Disorders

5.2.7 Other Diseases

5.3 By Product

5.3.1 Probiotics

5.3.2 Prebiotics

5.3.3 Symboitics

5.3.4 Other Products

5.4 Geography

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

6.1.1 AOBiome

6.1.2 Astarte Medical

6.1.3 Axial Biotherapeutics

6.1.4 DuPont

6.1.5 Enterome Bioscience

6.1.6 Evelo Biosciences

6.1.7 Finch Therapeutics

6.1.8 Ginkgo Bioworks

6.1.9 Nextbiotix

6.1.10 Osel Inc.

6.1.11 Second Genome Inc.

6.1.12 Seres Therapeutics

6.1.13 Synlogic Inc.

6.1.14 Synthetic Biologics Inc.

6.1.15 Yakult Honsha Co., Ltd.

6.1.16 Zymergen

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/g7hsof

View source version on businesswire.com: https://www.businesswire.com/news/home/20210302005739/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900